Swedish pharmaceutical company Moberg Pharma AB (STO: MOB) on Monday announced that it has published new analyses showing potent antifungal activity of terbinafine against dermatophytes causing onychomycosis.
The company said its topical onychomycosis treatment MOB-015 achieved mycological cure across the full range of baseline terbinafine susceptibility, including in patients with reduced in vitro susceptibility. MOB-015 has market approval in 14 countries and is sold in Sweden, Norway and Israel.
Moberg Pharma's findings are based on the completed North American Phase 3 study of daily MOB-015 treatment over 48 weeks, covering 506 dermatophyte isolates. Only 3.2% of baseline isolates showed elevated MIC values of at least 0.5 µg/ml. Among MOB-015-treated patients with evaluable end-of-study results, 74.3% achieved mycological cure, including two of three patients with elevated baseline MIC values.
The analyses were conducted with Professor Mahmoud Ghannoum at Case Western Reserve University in Ohio. The article, In Vitro Terbinafine Susceptibility of Dermatophytes and Mycological Cure Outcomes from a Multicenter Phase III Onychomycosis Trial, appears in Journal of Fungi (2026, 12(10), 739).
Merck partners with Isomorphic Labs on AI-driven oncology drug discovery
Dicot Pharma secures EU approval to advance LIB-01 phase 2b study
NFL Biosciences enrolls first participant in Phase 2 smoking cessation trial
Anixa Biosciences and Curia to finalise formulation of breast cancer vaccine for Phase 2 trial
Akagera Medicines receives Gates Foundation grant expansion to advance tuberculosis vaccine
Ten63 Therapeutics launches BEYOND-Alpha early adopter programme
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial